logo

Esperion Therapeutics (ESPR)



Trade ESPR now with
  Date
  Headline
8/2/2018 7:28:55 AM Esperion Q2 Net Loss $45.7 Mln Or $1.71 Per Share
5/23/2018 8:28:30 AM Esperion Therapeutics Trading Expected To Resume At 8:45 AM ET
5/23/2018 8:21:42 AM Esperion Says Third Pivotal Phase 3 Study Of Bempedoic Acid Meets Primary Endpoint
5/23/2018 8:12:54 AM Esperion Therapeutics Trading Halted; Pending News
5/2/2018 7:41:30 AM Esperion Therapeutics Trading Halted; Expected To Resume At 8:00 AM ET
5/2/2018 7:41:11 AM Esperion Q1 Net Loss Widens To $46.1 Mln From $40.5 Mln Last Year
5/2/2018 7:31:54 AM Esperion Announces Positive Top-Line Results From Pivotal Phase 3 Long-Term Safety Study Of Bempedoic Acid
3/27/2018 7:34:08 AM Esperion Reports Positive Top-line Results From Phase 2 Clinical Study (1002-039)
3/7/2018 7:30:41 AM Esperion Announces Positive Top-Line Results From First Pivotal Phase 3 Study Of Bempedoic Acid
12/14/2017 4:39:10 PM Esperion Appoints Jeffrey Berkowitz To Board Of Directors
11/7/2017 3:36:17 PM Jefferies Is Increasing Esperion Therapeutics (ESPR) FY18 Estimate To -8.54 From -9.36
11/7/2017 3:35:58 PM Jefferies Is Increasing Esperion Therapeutics (ESPR) FY17 Estimate To -7.43 From -7.45